If you have been reading about copper tripeptide-1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide was first isolated from human albumin in 1973 by Loren Pickart, who later described its copper-binding behavior. Early work linked the complex to wound healing and tissue remodeling. Plasma levels of GHK decline with age, a pattern that stimulated interest in topical and supplemental applications. Researchers have reported that the tripeptide influences collagen synthesis, antioxidant defense, and inflammatory signaling in cell and animal models. Human clinical evidence remains limited and often relies on small studies.
Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II) tripeptide complex | Contains glycyl-histidyl-lysine ligand |
| Peptide sequence | Gly-His-Lys | N-terminal glycine, C-terminal lysine |
| Molecular formula | C14H22CuN6O4 | Commonly cited for the 1:1 complex |
| Appearance | Blue to blue-violet solid | Color arises from copper d-d transitions |
| Solubility | Water-soluble | Also dissolves in some polar solvents |
Identity and purity are established with a combination of chromatographic and spectroscopic techniques. Reversed-phase high-performance liquid chromatography separates the intact complex from peptide fragments and free copper, and the elution profile yields a purity estimate. Mass spectrometry gives the mass of the intact species and exposes degradation products. Ultraviolet-visible spectroscopy displays a broad absorption band in the visible region that is characteristic of the copper center. Nuclear magnetic resonance is less informative here, because the paramagnetic metal broadens signals and complicates spectral interpretation.
Copper content is measured separately, since a peptide assay alone does not report the metal-to-peptide ratio. Elemental techniques such as inductively coupled plasma optical emission spectroscopy quantify copper after acid digestion of the sample. The result is compared with the theoretical value for a one-to-one complex, and a shortfall indicates free peptide or partial dissociation. Suppliers differ in how they state purity, as some quote peptide content and others quote the whole complex. A defined stoichiometry therefore requires both a peptide assay and a copper assay.
Solid GHK-Cu is usually supplied as a lyophilized powder and is kept cold and dry. Moisture, light, and repeated temperature cycling shorten its useful life in the laboratory. In aqueous solution the complex undergoes slow hydrolysis of the peptide backbone and gradual loss of coordinated copper. Buffers containing strong chelators, such as EDTA, compete for the metal and strip it from the peptide. Working solutions are therefore prepared shortly before use, and leftover liquid is not returned to the stock container.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence found naturally in human plasma, saliva and urine. Loren Pickart reported the isolation of the free peptide in 1973 while studying factors that influenced the growth of aged liver cells in culture. The peptide was later shown to bind copper(II) with high affinity, and the metal-bound form became the focus of most subsequent research. Its concentration in circulation declines markedly with age, a pattern that is well documented, though the physiological consequences of that decline remain debated.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
The sequence now called GHK was first reported in the early 1970s after isolation from human plasma, where it was noted to influence liver cell behavior in laboratory preparations. Later work described a copper-binding form and its activity in fibroblast and wound-model experiments. Review articles frequently group the substance with other copper peptides. Concentrations in blood appear to fall with age in several small surveys, although the reason for this trend is not settled. Whether such a decline carries functional consequences remains an open question.
Published work on GHK-Cu concentrates largely on cell culture systems rather than whole organisms. Frequently used endpoints include collagen synthesis, expression of matrix metalloproteinases, and migration of fibroblasts. Some reports describe antioxidant behavior, while others stress delivery of copper into cells. These mechanisms are proposed rather than demonstrated, and the relative weight of each pathway is unclear. Human trials are few and generally small, so laboratory findings should not be read as confirmed clinical results.
A small amount of blood (10 millilitres (0.35 imp fl oz; 0.34 US fl oz) per tube) is harvested and spun in a centrifuge for eight minutes at 1300 RPM. A fibrin clot packed with blood-derived growth factors, extracellular matrix and hematopoietic stem cells is fabricated and implanted into the gums above the area of gum recession. Advanced platelet-rich fibrin stimulates tissue growth in the patient's own gums eliminating the need to harvest tissue from the palate or the use of allografting.
=== Vagus nerve stimulation === Vagus nerve stimulation (VNS) uses an implanted electrode and generator to deliver electrical pulses to the vagus nerve, one of the primary nerves emanating from the brain. It is an approved therapy for treatment-resistant depression in the EU and US and is sometimes used as an adjunct to existing antidepressant treatment. The support for this method comes mainly from open-label trials, which indicate that several months may be required to see a benefit. The only large double-blind trial conducted lasted only 10 weeks and yielded inconclusive results; VNS failed to show superiority over a sham treatment on the primary efficacy outcome, but the results were more favorable for one of the secondary outcomes. The authors concluded "This study did not yield definitive evidence of short-term efficacy for adjunctive VNS in treatment-resistant depression."
These were not ready until 1901, the year after the system first opened, and Guimard varied the "Métropolitain" lettering somewhat between stations and twice revised the design, which reached its final form in 1902.
Sources: en.wikipedia.org
=== Industrial uses === The iron compounds produced on the largest scale in industry are iron(II) sulfate (FeSO4·7H2O) and iron(III) chloride (FeCl3). The former is one of the most readily available sources of iron(II), but is less stable to aerial oxidation than Mohr's salt ((NH4)2Fe(SO4)2·6H2O). Iron(II) compounds tend to be oxidized to iron(III) compounds in the air.
=== Gastrointestinal bleeding === The ratio is useful for the diagnosis of bleeding from the gastrointestinal (GI) tract in patients who do not present with overt vomiting of blood. In children, a BUN:Cr ratio of 30 or greater has a sensitivity of 68.8% and a specificity of 98% for upper gastrointestinal bleeding. A common assumption is that the ratio is elevated because of amino acid digestion, since blood (excluding water) consists largely of the protein hemoglobin and is broken down by digestive enzymes of the upper GI tract into amino acids, which are then reabsorbed in the GI tract and broken down into urea. However, elevated BUN:Cr ratios are not observed when other high protein loads (e.g., steak) are consumed. Renal hypoperfusion secondary to the blood lost from the GI bleed has been postulated to explain the elevated BUN:Cr ratio. However, other research has found that renal hypoperfusion cannot fully explain the elevation.
==== Spontaneous fermentation ==== Lambic beers are historically brewed in Brussels and the nearby Pajottenland region of Belgium without any yeast inoculation. The wort is cooled in open vats (called "coolships"), where the yeasts and microbiota present in the brewery (such as Brettanomyces) are allowed to settle to create a spontaneous fermentation, and are then conditioned or matured in oak barrels for typically one to three years.
British-trained Polish Cichociemni agent Maciej Kalenkiewicz was killed by the Soviets at this time. The British and Soviets sponsored competing factions of resistance fighters in Yugoslavia and Greece, although both ceased after Churchill and Stalin made the Percentages Agreement. Both sides, moreover, held very dissimilar ideas regarding the establishment and maintenance of post-war security. The Americans tended to understand security in situational terms, assuming that, if US-style governments and markets were established as widely as possible, countries could resolve their differences peacefully, through international organizations. The key to the US vision of security was a post-war world shaped according to the principles laid out in the 1941 Atlantic Charter—in other words, a liberal international system based on free trade and open markets. This vision would require a rebuilt capitalist Europe, with a healthy Germany at its center, to serve once more as a hub in global affairs. This would also require US economic and political leadership of the postwar world. Europe needed the US's assistance if it was to rebuild its domestic production and finance its international trade. The US was the only world power not economically devastated by the fighting. By the end of the war, it was producing around fifty percent of the world's industrial goods. Soviet leaders, however, tended to understand security in terms of space.
Sources: en.wikipedia.org
GHK is the free tripeptide, while GHK-Cu includes a bound copper(II) ion. The copper complex is the form most often studied for skin and wound-related activity. The two names are sometimes used interchangeably in product labeling, but they refer to distinct chemical species.
Yes, it is found in human plasma, saliva, and urine. Its concentration in plasma tends to decrease with age. This natural presence is one reason researchers have investigated its role in tissue maintenance.
No, GHK-Cu is not an approved drug in major markets. It is widely used as a cosmetic ingredient, where it is listed under names such as copper tripeptide-1. Any therapeutic claims would require separate regulatory review.
Dry powder is best kept cold, dark and sealed, typically at -20 °C for long-term storage or 2 to 8 °C for material in regular use. Vials should be warmed to room temperature before opening to prevent moisture condensing on the contents. Aqueous stock solutions degrade faster and are usually prepared fresh.